Results from work to develop a Parsortix-based Her2 assay kit showcased at International Liquid Biopsy Conference
Guildford, Surrey / Accesswire / November 15, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in San Diego, US from 13 to 16 November 2024.
Development of a scoring system to classify HER2 protein expression in circulating tumor cells through immunofluorescence following isolation using Parsortix® instruments
ANGLE is presenting a poster entitled the “Development of a scoring system to classify HER2 protein expression in Circulating Tumor Cells through immunofluorescence following isolation using Parsortix® instruments” and reports on progress of the Company’s co-development programme with BioView.
The Parsortix-based HER2 kit is being developed to provide an optimised, easily implemented solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancer.
The new data presented at the conference showcases the advancements made in the development of this kit and highlights the potential impact it could have on the field of liquid biopsy and cancer research.
By using Parsortix® instruments in conjunction with a scoring system to classify HER2 protein expression in circulating tumor cells, researchers and clinicians will have a more accurate and efficient way to assess and monitor HER2 status in breast cancer patients.
This could lead to earlier detection of HER2-positive breast cancer, more personalized treatment plans, and ultimately better outcomes for patients.
ANGLE’s collaboration with BioView further enhances the development of this kit, bringing together expertise in liquid biopsy technologies and imaging solutions to create a comprehensive and effective assay for HER2 assessment.
Overall, the results from this work demonstrate the potential of the Parsortix-based HER2 kit to revolutionize how HER2 status is assessed in breast cancer patients, leading to improved patient care and outcomes.
How this will affect me:
As a potential breast cancer patient, the development of the Parsortix-based HER2 kit could have a significant impact on your diagnosis and treatment plan. With a more accurate and efficient way to assess HER2 status, you may receive more personalized and effective treatment, ultimately leading to better outcomes.
How this will affect the world:
The development of the Parsortix-based HER2 kit has the potential to revolutionize the field of liquid biopsy and cancer research. By providing a more optimized and easily implemented solution for HER2 assessment, this kit could lead to earlier detection of HER2-positive breast cancer, more personalized treatment plans, and improved outcomes for patients worldwide.
Conclusion:
The results from the work to develop the Parsortix-based HER2 kit showcased at the International Liquid Biopsy Conference highlight the potential of this assay to transform how HER2 status is assessed in breast cancer patients. With advancements in technology and collaboration with industry partners, ANGLE plc is paving the way for more personalized and effective breast cancer treatment, ultimately improving patient care and outcomes.
